

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Patient Experiences of Co-Designed Rehabilitation Interventions: Protocol for a Rapid Review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056927
Article Type:	Protocol
Date Submitted by the Author:	03-Sep-2021
Complete List of Authors:	McKercher, Jonathan; Victorian Rehabilitation Centre, Physiotherapy; La Trobe University, ARCH Slade, Susan C.; La Trobe University, ARCH Jazayeri, Jalal; La Trobe University, ARCH Hodge, Anita; Healthscope Limited Knight, Matthew; Victorian Rehabilitation Centre; La Trobe University, ARCH Green, Janet; Healthscope Limited; La Trobe University Woods, Jeffrey; Healthscope Limited; La Trobe University, ARCH Morris, Meg; La Trobe University, ARCH; Healthscope Limited,
Keywords:	REHABILITATION MEDICINE, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

1-9-21

# Patient Experiences of Co-Designed Rehabilitation Interventions: Protocol for a Rapid Review

## Authors

Jonathan P. McKercher<sup>1,2</sup>, Susan C. Slade<sup>1,2</sup>, Jalal Jazayeri<sup>1</sup>, Anita Hodge<sup>3</sup>, Matthew Knight<sup>1</sup>, Janet Green<sup>4,5</sup>, Jeffrey Woods<sup>3</sup>, Meg E. Morris\*<sup>1,2</sup>

## Institutional Affiliations and Addresses

\*Corresponding author Professor Meg E. Morris

Mailing address: Academic and Research Collaborative in Health (ARCH), La Trobe University, Kingsbury Drive, Bundoora, Australia, 3086

Email: [m.morris@latrobe.edu.au](mailto:m.morris@latrobe.edu.au)

## Author affiliations:

1. The Victorian Rehabilitation Centre, Healthscope, 499 Springvale Rd, Glen Waverley, VIC, 3150, Australia.
2. La Trobe University Academic and Research Collaborative in Health (ARCH), Bundoora, VIC, 3086, Australia.
3. Healthscope, 312 St Kilda Rd, Melbourne, VIC, 3000, Australia.
4. School of Nursing, College of Health and Medicine, University of Tasmania, Australia.
5. The Hills Private Hospital, Healthscope, 499 Windsor Rd, Baulkham Hills, NSW, 2153, Australia.

Email: JPM	<a href="mailto:J.McKercher@latrobe.edu.au">J.McKercher@latrobe.edu.au</a>	ORCID: 0000-0002-8839-8353
SCS	<a href="mailto:s.slade2@latrobe.edu.au">s.slade2@latrobe.edu.au</a>	ORCID: 0000-0001-6325-2705
JJ	<a href="mailto:jalalale@gmail.com">jalalale@gmail.com</a>	ORCID: 0000-0001-8795-6520
AH	<a href="mailto:anita.hodge@healthscope.com.au">anita.hodge@healthscope.com.au</a>	
MK	<a href="mailto:matthew.knight@healthscope.com.au">matthew.knight@healthscope.com.au</a>	
JG	<a href="mailto:jgr54354@gmail.com">jgr54354@gmail.com</a>	ORCID: 0000-0002-2938-6694
JW	<a href="mailto:jeffrey.woods@healthscope.com.au">jeffrey.woods@healthscope.com.au</a>	
MEM	<a href="mailto:m.morris@latrobe.edu.au">m.morris@latrobe.edu.au</a>	ORCID: 0000-0002-0114-4175

**Key Words:** rehabilitation, co-design, patient experience, rapid review, quality

**Manuscript Word Count:** 1758

1-9-21

**1 ABSTRACT**

**2 Introduction:** Patient-centred care can be facilitated by co-design, which refers to  
3 collaboration between healthcare professionals and consumers in producing and  
4 implementing healthcare. Systematic reviews on co-design have mainly focused on the  
5 effectiveness of co-produced healthcare interventions. Less attention has been directed  
6 towards the experiences of patients in co-designed interventions. This rapid review aims to  
7 explore patient experiences of co-designed rehabilitation interventions and inform  
8 rehabilitation decision-making.

**9 Methods and analysis:** A rapid review will expedite timely information on co-design  
10 experiences for stakeholders. Four electronic databases, including Cochrane CENTRAL,  
11 MEDLINE, Embase, and CINAHL, will be searched from 1 January 2000 to 1 July 2021.  
12 The Cochrane Risk of Bias tool will be used for randomised trials. Critical appraisal  
13 checklists from The Joanna Briggs Institute shall evaluate the risk of bias of non-randomised  
14 trials and qualitative studies. A narrative synthesis will be provided for the quantitative  
15 studies. Thematic synthesis will be conducted on qualitative findings. The overall strength  
16 evidence will be measured using the GRADE framework for quantitative investigations and  
17 the GRADE-CERQual for qualitative studies. The results will be presented textually, with  
18 flow charts, summary tables, statistical analysis, narrative summaries and identified themes.

**19 Ethics and dissemination:** Ethics approval is not required for the review. The protocol and  
20 rapid review will be submitted to a peer-reviewed journal for publication. The review  
21 findings will be rapidly translated to consumers, clinicians, healthcare leaders, organisations,  
22 researchers and policy makers via publications, evidence summaries, conferences,  
23 workshops, websites, social media, and online events.

24 1. • Your submission should include a title page (embedded in the main document) which must  
25 contain the following information:

26

1-9-21

1  
2  
3 1 **Article Summary**

4  
5 2 **Registration details:** This protocol has been published on PROSPERO: CRD42021264547.  
6  
7 3

8  
9 4 **Strengths and limitations of this study:**

- 10  
11  
12 5 • Timely evidence generated on the relationships between co-designed rehabilitation  
13  
14 6 interventions and patient experiences will inform policies and rehabilitation practice.  
15  
16 7 • Co-production and co-authorship with consumers are strengths of this study.  
17  
18  
19 8 • Rapid knowledge synthesis will accelerate the translation of evidence into  
20  
21 9 rehabilitation practice.  
22  
23  
24 10 • Risk of bias may be introduced by rapid methods and will be controlled for by *a*  
25  
26 11 *priori* recommended methods and transparent reporting of the results.  
27  
28 12  
29  
30  
31 13  
32  
33  
34 14  
35  
36  
37 15  
38  
39  
40 16  
41  
42  
43 17  
44  
45  
46 18  
47  
48  
49 19  
50  
51  
52 20  
53  
54  
55 21  
56  
57  
58 22  
59  
60

1-9-21

## 1 INTRODUCTION

2 Patient-centred care is integral to the delivery of high-quality healthcare and positive patient  
3 experiences.<sup>1</sup> Facilitating patient participation across all levels of health service ecosystems is  
4 key for safe and effective patient-centred care.<sup>2</sup> Wolfe et al. (2014) defined patient  
5 experiences as "...the sum of all interactions, shaped by the organisation's culture, that  
6 influence patient perceptions, across the continuum of care."<sup>3</sup> Consumer participation is the  
7 gold-standard for person-centred care.<sup>4</sup>

8  
9 Rehabilitation is a person-centred approach which tailors interventions to the individual and  
10 involves an interdisciplinary team.<sup>5</sup> Rehabilitation interventions are designed to improve  
11 mobility and independence, minimise pain, and to improve a person's ability to adapt to  
12 changes in circumstances.<sup>5</sup> Rehabilitation also aims to optimise movement, strength,  
13 function, upper limb control, balance and to facilitate timely discharge.<sup>6</sup> Various methods can  
14 be used to improve patient experiences of rehabilitation.<sup>7</sup> One approach is co-design, which  
15 refers to collaboration between healthcare professionals and consumers to design and  
16 implement therapies and services.<sup>8</sup> Rehabilitation designed in partnership with patients is  
17 more likely to meet their needs and preferences.<sup>9</sup> The National Institute for Health Research  
18 (NIHR) in the United Kingdom, and similar agencies, have advocated co-design.<sup>9-12</sup>

19  
20 Previous reviews of co-design in healthcare have centred around consumer needs;<sup>1,8,10,13,14</sup>  
21 implementing co-designed interventions to influence health professional behaviour;<sup>8</sup>  
22 evaluation of how co-design facilitates clinical and service outcomes in acute healthcare  
23 settings;<sup>14</sup> and outcomes for different co-designed hospitals tools, therapies and services.<sup>10</sup>

24  
25 The primary aim of this review is to explore patient experiences of co-designed interventions

1-9-21

1  
2  
3 1 in rehabilitation hospitals. Secondary aims will be to understand (i) the methods used to co-  
4  
5 2 design rehabilitation interventions; (ii) the ways in which co-designed rehabilitation  
6  
7 3 interventions are implemented; and (iii) the barriers and facilitators to implementing co-  
8  
9 4 designed rehabilitation therapies.

## 6 **METHODS AND ANALYSIS**

7 Systematic reviews provide high-quality evidence syntheses to appraise policy and clinical  
8  
9 8 practice.<sup>15,16</sup> A rapid review is an evidence synthesis that provides information to decision  
10  
11 9 makers in a timely manner, allowing for rapid communication of research findings to end-  
12  
13 10 users.<sup>17</sup> Components of a standard systematic review are streamlined in a rapid review.<sup>18</sup>  
14  
15 11 Rapid reviews are particularly valuable when stakeholders and policy makers have a short  
16  
17 12 deadline for evidence and advice.<sup>16,17</sup> It is noteworthy that rapid reviews are rigorous and are  
18  
19 13 not less systematic than standard systematic reviews.<sup>19</sup> The Cochrane Rapid Review Methods  
20  
21 14 Group gives recommendations on the methodology supporting rapid reviews.<sup>17,18</sup> These  
22  
23 15 include a reduced number of reviewers for screening, streamlining data extraction, and  
24  
25 16 method quality appraisal processes, and restricting the inclusion criteria to a defined date  
26  
27 17 range.<sup>17</sup> They also recommend limiting databases searched and minimising grey literature and  
28  
29 18 supplemental searching.<sup>18</sup>

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47 20 The current protocol has been published on the international prospective register of  
48  
49 21 systematic reviews (PROSPERO: CRD42021264547) for registration, in compliance with the  
50  
51 22 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)  
52  
53 23 recommendations.<sup>20</sup> In the absence of a published reporting guideline for rapid reviews,<sup>15</sup> the  
54  
55 24 protocol will be informed by the PRISMA-P guidelines and the Cochrane Rapid Review  
56  
57 25 methods.<sup>18,20</sup> The review methods will also be guided by the Cochrane Rapid Review  
58  
59  
60

1-9-21

1  
2  
3 1 Methods Group best practice recommendations and the Preferred Reporting Items for  
4  
5 2 Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>18,21</sup> The Enhancing  
6  
7 3 Transparency in Reporting the synthesis of Qualitative research (ENTREQ) guideline will be  
8  
9 4 used to apprise the reporting of qualitative elements of the evidence synthesis.<sup>22</sup>  
10  
11  
12 5

## 6 **Patient and public involvement**

7 This protocol has been co-designed and co-authored with two consumer representatives.  
8 Consumers offer an authentic lived-experience contribution, and the consumer  
9 representatives assisted in the conceptualisation of the protocol, the refinement of the  
10 research question, and the editing of the manuscript. The consumers will also provide input  
11 into the evidence synthesis and assist in writing the final manuscript for the rapid review.  
12

## 13 **Eligibility criteria**

14 Studies are to be included when they meet the following criteria: participants who are adults  
15 older than 18 years; rehabilitation interventions co-designed with patients; patient  
16 experiences of co-designed rehabilitation interventions are reported; inpatient hospital  
17 settings; empirical study design reported in English. Publications will be excluded if they are  
18 protocols, book chapters, theses, editorials, conference abstracts or studies that include  
19 participants in a paediatric population or patient groups that require a third party to participate  
20 in the co-design process (e.g., individuals with severe cognitive impairment).  
21

## 22 **Identification and selection of included papers**

23 A health services librarian will develop the search strategies and run the electronic database  
24 searches. Four online databases (Cochrane CENTRAL, MEDLINE, Embase, and CINAHL)  
25 will be searched from 1 January 2000 to 1 October 2021. Search terms for the following key  
26 concepts will be used: co-design; rehabilitation interventions; consumers and patients; patient



1-9-21

1  
2  
3 1 experience; hospitals and acute health care settings. An example search is in the  
4  
5 2 supplementary file (appendix 1).  
6  
7 3  
8

9 4 The search results will be downloaded to EndNote X9.3.1.<sup>23</sup> The combined yield will be  
10  
11 5 uploaded into Covidence to sort and select the studies against the eligibility criteria.<sup>24</sup> Initially  
12  
13 6 the duplicates will be deleted in Covidence then titles alone will be screened for eligibility.  
14  
15 7 The remaining titles with abstracts will then be screened in Covidence. At least one quarter of  
16  
17 8 the titles with abstracts will be screened by two reviewers through applying the eligibility  
18  
19 9 criteria.<sup>17</sup> The remaining titles with abstracts will be screened by one reviewer. After reaching  
20  
21 10 consensus on the yield, the full texts will be obtained for the remaining abstracts. The full  
22  
23 11 texts will be saved in Covidence, read in full by at least one reviewer and screened using the  
24  
25 12 eligibility criteria. A second reviewer will screen the excluded abstracts and full text studies  
26  
27 13 and the two reviewers will meet to reach consensus.<sup>17</sup> Reasons for exclusions will be noted in  
28  
29 14 Covidence. Any discrepancies or disagreements that arise during this process will be resolved  
30  
31 15 by consultation and consensus with a third author. A PRISMA-compliant flow chart (online  
32  
33 16 supplementary appendix 2) generated through Covidence, will record the selection process  
34  
35 17 for the included studies.  
36  
37  
38  
39  
40  
41  
42  
43

#### 19 **Method quality assessment**

44  
45  
46 20 The Cochrane Risk of Bias tool will be used to appraise the method quality for the  
47  
48 21 randomised controlled clinical trials.<sup>25</sup> Critical appraisal checklists from The Joanna Briggs  
49  
50 22 Institute (JBI) critical appraisal tools will be completed to assess the risk of bias, matched to  
51  
52 23 the quantitative or qualitative designs of the included studies.<sup>26,27</sup> Two reviewers will assess  
53  
54 24 the included studies using the Cochrane Risk of Bias tool or relevant JBI critical appraisal  
55  
56 25 checklist to independently assess the trustworthiness of included studies.<sup>25,26</sup> The checklists  
57  
58 26 include a series of questions which will help the reviewers to determine the risk of bias and  
59  
60

1-9-21

1  
2  
3 1 the trustworthiness of the reported results. Each checklist has a comprehensive guide for each  
4  
5 2 item.<sup>26,28</sup>  
6  
7  
8  
9  
10

#### 4 **Data extraction and management**

11  
12 5 Two reviewers will independently extract the data into spreadsheets using headings such as:  
13  
14 6 study design, country, first author, year, setting, sample size, participant characteristics,  
15  
16 7 intervention characteristics (content, who delivered, dosage etc.), co-design strategies used,  
17  
18 8 description of co-design implementation, primary and secondary outcome measures such as  
19  
20 9 patient experience and effects of co-production, outcome data and results, themes, co-design  
21  
22 10 barriers, and co-design facilitators. The data extraction spreadsheets will be evaluated for  
23  
24 11 consistency and any disagreements will be discussed and agreed upon. The spreadsheets will  
25  
26 12 then be combined for the data synthesis stage.  
27  
28  
29  
30  
31

#### 14 **Data analysis/synthesis**

32  
33  
34 15 Data analysis will be independently completed by two reviewers. For the quantitative data, a  
35  
36 16 narrative synthesis will be used and reported according to the Synthesis without Meta-  
37  
38 17 Analysis (SWiM).<sup>29</sup> Two reviewers will independently summarise and interpret the reported  
39  
40 18 results for the included studies. A textual description will be provided for each study to give  
41  
42 19 details on the setting, participants, intervention, and findings such as effect sizes or mean  
43  
44 20 changes.<sup>26</sup>  
45  
46  
47  
48  
49  
50  
51

52  
53 22 For the qualitative data, a thematic synthesis will be used within a theoretical framework of  
54  
55 23 meta-synthesis and an analytical framework of thematic analysis.<sup>30</sup> The three stages of  
56  
57 24 thematic synthesis recommended by Harden and Thomas (2008) will be used for combined  
58  
59 25 analysis of the primary studies.<sup>31</sup> This includes coding the findings of the included studies  
60

1-9-21

1  
2  
3 1 and developing descriptive themes for the combined coding; identifying relationships  
4  
5 2 between the descriptive themes; and generating analytical themes which transcend the  
6  
7 3 content of each original study.<sup>31</sup> This synthesis approach is supported by the Cochrane  
8  
9 4 Qualitative and Implementation Methods Group recommendations. They advise descriptive  
10  
11 5 themes often inform policy and analytical themes inform theory. Two reviewers will  
12  
13 6 independently read the included studies to code and extract the themes reported by the  
14  
15 7 authors of each paper. The reviewers will then group themes according to their similarities,  
16  
17 8 forming representative themes. From the consolidated themes, analytical themes will be  
18  
19 9 developed independently by each reviewer and finalised by consensus.<sup>31</sup> Summary tables will  
20  
21 10 be used for the qualitative findings. Any discrepancies between the two reviewers will be  
22  
23 11 settled by a third author.  
24  
25  
26  
27  
28  
29

### 30 **Confidence in cumulative evidence**

31  
32 14 PRIMSA-P recommends that the overall strength of included studies be assessed.<sup>20</sup> For  
33  
34 15 randomised controlled clinical trials and observational studies, the Grading of  
35  
36 16 Recommendations Assessment, Development and Evaluation (GRADE) framework will be  
37  
38 17 utilised.<sup>32</sup> This provides a quality of evidence rating system for each review outcome. The  
39  
40 18 results will be displayed in a table summarising the findings.<sup>32</sup>  
41  
42  
43  
44 19  
45  
46 20 Where the included studies are of a qualitative design, the strength of the findings will be  
47  
48 21 measured using the GRADE-CERQual (Confidence in Evidence from Reviews of Qualitative  
49  
50 22 Research).<sup>33</sup> The GRADE-CERQual is a framework for reviewers to assess the amount of  
51  
52 23 confidence they can have in the review results from qualitative syntheses.<sup>33</sup> Two reviewers  
53  
54 24 (JPM, SCS) will independently perform a GRADE-CERQual assessment of the findings of  
55  
56 25 each review.  
57  
58  
59  
60

1-9-21

## 1 **RESULTS**

2 The quantitative results will be presented textually, with flow charts, summary tables,  
3 statistical analysis and narrative summaries. The qualitative results will be presented as  
4 themes and subthemes and summary tables linked to the data.

## 6 **DISCUSSION**

7 The rationale and design of a rapid review of patient experiences of co-design of  
8 rehabilitations interventions has been described. The review will identify important factors in  
9 co-production and inform optimum intervention design for rehabilitation.

## 11 **ETHICS AND DISSEMINATION**

12 Ethics approval will not be required for the protocol and rapid review. The protocol and  
13 accompanying review will be submitted to an international peer-reviewed journal for  
14 publication. The findings will be rapidly translated to consumers, clinicians, healthcare  
15 leaders, organisations, and the research community and policy makers via publications,  
16 evidence summaries, conferences, workshops, websites, social media, and online events.

## 18 **Acknowledgements**

19 We thank Elizabeth Lawrence, La Trobe University librarian, for developing and conducting  
20 the search of the literature.

## 22 **Author Contribution**

23 JPM, SCS, JJ, and MEM contributed to the conceptualisation of the study, research question  
24 and study design. JPM wrote the first draft of the protocol manuscript. JPM, SCS, and MEM  
25 contributed to the subsequent drafts of the manuscript. The final draft was edited and  
26 approved by all authors prior to submission (JPM, SCS, JJ, AH, MK, JG, JW and MEM).

1-9-21

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Funding:** This project was funded by the La Trobe University, Academic and Research  
2 Collaborative in Health (ARCH).

4 **Competing interests:** None declared

6 **Data statement:** Data sharing is not applicable as no participant datasets will be generated  
7 and/or analysed for this study.

For peer review only

1-9-21

1  
2  
3 **1 REFERENCE LIST**

- 4  
5  
6 2 1. Bombard Y, Baker GR, Orlando E, et al. Engaging patients to improve quality of  
7  
8 3 care: a systematic review. *Implementation Science*. 2018;13(1):98.
- 9  
10 4 2. Merner B, Hill S, Colombo C, et al. Consumers and health providers working in  
11  
12 5 partnership for the promotion of person-centred health services: a co-produced  
13  
14 6 qualitative evidence synthesis. *Cochrane Database of Systematic Reviews*. 2019(2).
- 15  
16 7 3. Wolfe JA, Niederhauser V, Marshburn D, LaVela S. Defining patient experience.  
17  
18 8 *Patient Experience Journal*. 2014;1(1).
- 19  
20 9 4. (ACSQHC) ACoSaQihC. Partnering with consumers standard.  
21  
22 10 47  
48 23 Codesign-Capability.pdf.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1-9-21

- 1  
2  
3 1 10. Lim S, Morris H, Pizzirani B, Kajewski D, Lee WK, Skouteris H. Evaluating hospital  
4  
5 2 tools and services that were co-produced with patients: A rapid review. *Int J Qual*  
6  
7 3 *Health Care*. 2020;32(4):231-239.  
8  
9 4 11. Wolstenholme D, Grindell C, Dearden A. A co-design approach to service  
10  
11 5 improvement resulted in teams exhibiting characteristics that support innovation.  
12  
13 6 *Design for health (Abingdon, England)*. 2017;1(1):42-58.  
14  
15 7 12. Pelton L, Knihtila M. Experience-Based Co-Design of Health Care Services -  
16  
17 8 Implementation Guide. Institute for Healthcare Improvement. <http://www.ihl.org/>.  
18  
19 9 Published 2018. Accessed. 29 August 2021.  
20  
21 10 13. Slattery P, Saeri AK, Bragge P. Research co-design in health: a rapid overview of  
22  
23 11 reviews. *Health Research Policy and Systems*. 2020;18(1):17.  
24  
25 12 14. Clarke D, Jones F, Harris R, Robert G. What outcomes are associated with developing  
26  
27 13 and implementing co-produced interventions in acute healthcare settings? A rapid  
28  
29 14 evidence synthesis. *BMJ Open*. 2017;7(7):e014650.  
30  
31 15 15. Stevens A, Garritty C, Hersi M, Moher D. Developing PRISMA-RR, a reporting  
32  
33 16 guideline for rapid reviews of primary studies (Protocol). 2018.  
34  
35 17 16. Higgins J, Green S, Cochrane C, Wiley I, NetLibrary I. *Cochrane handbook for*  
36  
37 18 *systematic reviews of interventions*. Chichester, England; Hoboken, NJ: Wiley-  
38  
39 19 Blackwell; 2008.  
40  
41 20 17. Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane Rapid Reviews  
42  
43 21 Methods Group offers evidence-informed guidance to conduct rapid reviews. *J Clin*  
44  
45 22 *Epidemiol*. 2021;130:13-22.  
46  
47 23 18. Garritty C, Gartlehner G, Kamel C, et al. Cochrane Rapid Reviews. Interim Guidance  
48  
49 24 from the Cochrane Rapid Reviews Methods Group. In: March 2020:  
50  
51 25 [https://methods.cochrane.org/rapidreviews/sites/methods.cochrane.org/rapidreviews/fi](https://methods.cochrane.org/rapidreviews/sites/methods.cochrane.org/rapidreviews/files/public/uploads/cochrane_rr_-_guidance-23mar2020-final.pdf)  
52  
53 26 [les/public/uploads/cochrane\\_rr\\_-\\_guidance-23mar2020-final.pdf](https://methods.cochrane.org/rapidreviews/sites/methods.cochrane.org/rapidreviews/files/public/uploads/cochrane_rr_-_guidance-23mar2020-final.pdf).

1-9-21

- 1  
2  
3 1 19. Moons P, Goossens E, Thompson DR. Rapid reviews: the pros and cons of an  
4  
5 2 accelerated review process. *European Journal of Cardiovascular Nursing*.  
6  
7 3 2021;20(5):515-519.  
8  
9 4 20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic  
10  
11 5 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*.  
12  
13 6 2015;4(1):1.  
14  
15  
16 7 21. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated  
17  
18 8 guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.  
19  
20  
21 9 22. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in  
22  
23 10 reporting the synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol*.  
24  
25 11 2012;12(1):181-181.  
26  
27  
28 12 23. Endnote reference management software, Clarivate Analytics. [www.endnote.com](http://www.endnote.com).  
29  
30 13 Accessed. 29 August 2021.  
31  
32 14 24. Covidence systematic review software, Veritas Health Innovation, Melbourne,  
33  
34 15 Australia. [www.covidence.org](http://www.covidence.org). Accessed.  
35  
36  
37 16 25. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of  
38  
39 17 bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919.  
40  
41  
42 18 26. Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. In: *JBI.2020*:  
43  
44 19 <https://synthesismanual.jbi.global>. <https://doi.org/10.46658/JBIMES-20-01>.  
45  
46  
47 20 27. Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological  
48  
49 21 guidance for systematic reviewers utilizing meta-aggregation. *Int J Evid Based*  
50  
51 22 *Healthc*. 2015;13(3):179-187.  
52  
53 23 28. Higgins J, Savović J, Page M, Elbers R, Sterne J. Chapter 8: Assessing risk of bias in  
54  
55 24 a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page  
56  
57 25 MJ, Welch VA (editors). In: *Cochrane Handbook for Systematic Reviews of*  
58  
59 26 *Interventions version 6.2 (updated February 2021)*. Cochrane, 2021.



1-9-21

- 1  
2  
3 1 29. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis  
4  
5 2 (SWiM) in systematic reviews: reporting guideline. *BMJ*. 2020;368:l6890.  
6  
7 3 30. Noyes J, Booth A, Cargo M, et al. Chapter 21: Qualitative evidence. In: Higgins JPT,  
8  
9 4 Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane*  
10  
11 Handbook for Systematic Reviews of Interventions version 6.2 (updated February  
12  
13 5 Handbook for Systematic Reviews of Interventions version 6.2 (updated February  
14  
15 6 2021). Cochrane, 2021. In.  
16  
17 7 31. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in  
18  
19 8 systematic reviews. *BMC Med Res Methodol*. 2008;8(1):45-45.  
20  
21 9 32. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE  
22  
23 10 evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-  
24  
25 11 394.  
26  
27  
28 12 33. Lewin S, Booth A, Glenton C, et al. Applying GRADE-CERQual to qualitative  
29  
30 13 evidence synthesis findings: introduction to the series. *Implementation Science*.  
31  
32 14 2018;13(1):2.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Appendix 1: Search Strategy:


Database(s): Ovid MEDLINE(R) ALL 1946 to June 2021

Search ID#	Search Terms	Search Notes	Results
1	(co-design* or codesign*).mp.		1614
2	(co-produc* or coproduc*).mp.		5418
3	(codevise* or cocreate* or co-create* or co-invent* or cogenerate* or co-found*).mp.		914
4	participatory design*.mp.		623
5	collaborative design*.mp.		138
6	("Experience based" adj2 design*).mp.		99
7	Decision Making, Shared/		1005
8	(share* adj2 "decision making").mp.		10869
9	or/1-8		19259
10	patient engagement.mp.		3550
11	patient involvement.mp.		2896
12	patient consultation.mp.		560
13	Patient Participation/		27250
14	patient participation.mp.		29017
15	patient input*.mp.		419
16	Stakeholder Participation/		1578
17	stakeholder participation.mp.		1906
18	consumer engagement.mp.		253
19	consumer involvement.mp.		357
20	consumer participation.mp.		414
21	consumer input.mp.		99
22	or/10-21		36540
23	design*.mp.		2282168
24	22 and 23	more general co-design terms AND "design"	7842
25	9 or 24	Co-design terms	26095
26	exp Hospitals/		287515
27	hospital*.tw.		1381782
28	Critical Care/		55257

29	Inpatients/		24172
30	inpatient*.mp.		128467
31	Hospitalization/		117596
32	hospitali?ation.mp.		234243
33	exp Hospital Units/		119558
34	ward*.tw,kw.		64380
35	((acute or subacute or sub-acute) adj3 (clinic* or care or department* or unit* or centre* or center*)).mp.		60190
36	Subacute Care/		1211
37	or/26-36	Hospital terms	1722776
38	(patient* adj2 (experience* or perception* or belief* or believe* or participat*)).mp.		170925
39	(consumer* adj2 (experience* or perception* or belief* or believe* or participat*)).mp.		2655
40	lived experience*.mp.		7501
41	38 or 39 or 40	Outcomes terms	180025
42	25 and 37 and 41		1790
43	limit 42 to (english language and yr="2000 -Current")		1592

NOTE: [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

Appendix 2: PRISMA flow Diagram:



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

# BMJ Open

## Patient Experiences of Co-Designed Rehabilitation Interventions: Protocol for a Rapid Review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056927.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Dec-2021
Complete List of Authors:	Mckercher, Jonathan; Victorian Rehabilitation Centre, Physiotherapy; La Trobe University, ARCH Slade, Susan C.; La Trobe University, ARCH Jazayeri, Jalal; La Trobe University, ARCH Hodge, Anita; Healthscope Limited Knight, Matthew; Victorian Rehabilitation Centre; La Trobe University, ARCH Green, Janet; Healthscope Limited; La Trobe University Woods, Jeffrey; Healthscope Limited; La Trobe University, ARCH Morris, Meg; La Trobe University, ARCH; Healthscope Limited,
<b>Primary Subject Heading</b>:	Rehabilitation medicine
Secondary Subject Heading:	Evidence based practice, Patient-centred medicine, Rehabilitation medicine, Nursing, Health services research
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, REHABILITATION MEDICINE

SCHOLARONE™  
Manuscripts

Revision 28 Dec 2021

# Patient Experiences of Co-Designed Rehabilitation Interventions: Protocol for a Rapid Review

## Authors

Jonathan P. McKercher<sup>1,2</sup>, Susan C. Slade<sup>1,2</sup>, Jalal Jazayeri<sup>1</sup>, Anita Hodge<sup>3</sup>, Matthew Knight<sup>1</sup>, Janet Green<sup>4,5</sup>, Jeffrey Woods<sup>3</sup>, Meg E. Morris\*<sup>1,2</sup>

## Institutional Affiliations and Addresses

\*Corresponding author Professor Meg E. Morris

Mailing address: Academic and Research Collaborative in Health (ARCH), La Trobe University, Kingsbury Drive, Bundoora, Australia, 3086

Email: [m.morris@latrobe.edu.au](mailto:m.morris@latrobe.edu.au)

## Author affiliations:

1. Victorian Rehabilitation Centre, Healthscope, 499 Springvale Rd, Glen Waverley, VIC, 3150, Australia.
2. La Trobe University Academic and Research Collaborative in Health (ARCH), Bundoora, VIC, 3086, Australia.
3. Healthscope, 312 St Kilda Rd, Melbourne, VIC, 3000, Australia.
4. School of Nursing, College of Health and Medicine, University of Tasmania, Australia.
5. The Hills Private Hospital, Healthscope, 499 Windsor Rd, Baulkham Hills, NSW, 2153, Australia.

Email: JPM	J.McKercher@latrobe.edu.au	ORCID: 0000-0002-8839-8353
SCS	s.slade2@latrobe.edu.au	ORCID: 0000-0001-6325-2705
JJ	jalalale@gmail.com	ORCID: 0000-0001-8795-6520
AH	anita.hodge@healthscope.com.au	ORCID 0000-0002-5716-8811
MK	matthew.knight@healthscope.com.au	
JG	jgr54354@gmail.com	ORCID: 0000-0002-2938-6694
JW	jeffrey.woods@healthscope.com.au	ORCID: 0000-0001-8050-6578
MEM	m.morris@latrobe.edu.au	ORCID: 0000-0002-0114-4175

**Key Words:** rehabilitation, co-design, patient experience, rapid review, quality

**Manuscript Word Count:** 2130

Revision 28 Dec 2021

1  
2  
3 1 **ABSTRACT**

4 2 **Introduction:** Patient-centred care can be facilitated by co-design, which refers to  
5 3 collaboration between healthcare professionals and consumers in producing and  
6 4 implementing healthcare. Systematic reviews on co-design have mainly focused on the  
7 5 effectiveness of co-produced healthcare interventions. Less attention has been directed  
8 6 towards the experiences of patients in co-designed interventions. This rapid review aims to  
9 7 explore patient experiences of co-designed rehabilitation interventions and inform  
10 8 rehabilitation decision-making.

11 9 **Methods and analysis:** A rapid review will expedite timely information on co-design  
12 10 experiences for stakeholders. Four electronic databases, including Cochrane CENTRAL,  
13 11 MEDLINE, Embase, and CINAHL, will be searched for papers published from 1 January  
14 12 2000 to 1 January 2022. The Cochrane Risk of Bias tool will be used for randomised trials.  
15 13 Critical appraisal checklists from The Joanna Briggs Institute shall evaluate the risk of bias of  
16 14 non-randomised trials and qualitative studies. A narrative synthesis will be provided for the  
17 15 quantitative studies. Thematic synthesis will be conducted on qualitative findings. The  
18 16 overall strength evidence will be measured using the GRADE framework for quantitative  
19 17 investigations and the GRADE-CERQual for qualitative studies. The results will be presented  
20 18 using narrative summaries, identified themes, summary tables, flow charts and quantitative  
21 19 statistical analyses.

22 20 **Ethics and dissemination:** Ethics approval is not required for the review. The protocol and  
23 21 rapid review will be submitted to an online, open access, and peer-reviewed journal for  
24 22 publication. The review findings will be rapidly translated to consumers, clinicians,  
25 23 healthcare leaders, organisations, researchers and policy makers via publications, evidence  
26 24 summaries, conferences, workshops, websites, social media, and online events.

Revision 28 Dec 2021

1  
2  
3 1 **Article Summary**

4  
5 2 **Registration details:** This protocol has been published on PROSPERO: CRD42021264547.  
6  
7 3

8  
9 4 **Strengths and limitations of this study:**

- 10  
11  
12 5 • Co-production and co-authorship with consumers are strengths of this study.  
13  
14 6 • Timely evidence generated by using rapid review methodology will accelerate the  
15  
16 7 translation of evidence into rehabilitation practice.  
17  
18 8 • Risk of bias can sometimes be introduced by rapid methods and will be controlled for  
19  
20 9 by *a priori* recommended methods and transparent reporting of the results.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Revision 28 Dec 2021

## 1 INTRODUCTION

2 Patient-centred care is integral to the delivery of high-quality healthcare and positive patient  
3 experiences.<sup>1</sup> Facilitating patient participation across health service ecosystems is key for safe  
4 and effective patient-centred care.<sup>2</sup> Wolfe et al. (2014) defined patient experiences as "...the  
5 sum of all interactions, shaped by the organisation's culture, that influence patient  
6 perceptions, across the continuum of care."<sup>3</sup> Consumer participation is the gold-standard for  
7 person-centred care, and can include co-design.<sup>4</sup> Co-design refers to collaboration between  
8 stakeholders such as patients, healthcare professionals, carers, or families to design and  
9 implement therapies and services in partnership.<sup>5</sup> Rehabilitation interventions are considered  
10 to be co-designed if a patient has participated in planning, design, or delivery, including the  
11 re-design of interventions to meet individual needs and preferences.

12  
13 Rehabilitation is a person-centred approach that tailors interventions to the individual and  
14 their goals, and involves an interdisciplinary team.<sup>6</sup> Movement rehabilitation interventions  
15 can be designed to improve mobility and independence, minimise pain, and to improve a  
16 person's ability to adapt to changes in circumstances.<sup>6</sup> Movement rehabilitation also aims to  
17 optimise movement, strength, function, upper limb control, balance and to facilitate timely  
18 discharge.<sup>7</sup> Various methods can be used to improve patient experiences of movement  
19 rehabilitation.<sup>8</sup> One approach is co-design, which refers to collaboration between healthcare  
20 professionals and consumers to design and implement therapies and services.<sup>5</sup> Rehabilitation  
21 designed in partnership with patients is more likely to meet their needs and preferences.<sup>9</sup> The  
22 National Institute for Health Research (NIHR) and other agencies across the globe have  
23 advocated co-design.<sup>9-12</sup>

24  
25 Previous reviews of co-design in healthcare have centred around consumer needs;<sup>1, 5, 10, 13, 14</sup>

Revision 28 Dec 2021

1  
2  
3 1 implementing co-designed interventions to influence health professional behaviours;<sup>5</sup>  
4  
5 2 evaluation of how co-design facilitates clinical and service outcomes in acute healthcare  
6  
7 3 settings;<sup>14</sup> and outcomes for different co-designed hospitals tools, therapies and services.<sup>10</sup> A  
8  
9 4 new area of research has been the use of co-design of mobile health (mHealth) interventions,  
10  
11 5 also known as digital health.<sup>15</sup> For example, one trial showed that a co-designed mHealth  
12  
13 6 system supported stroke rehabilitation by improving communication of health advice and  
14  
15 7 patient engagement.<sup>16</sup> A systematic literature review by Noorbergen et al.<sup>15</sup> showed that co-  
16  
17 8 designed strategies were of benefit to some rehabilitation patients. The literature emphasises  
18  
19 9 early co-design and there is a paucity of research on the post-design phase.<sup>15</sup> A focus on post-  
20  
21 10 design implementation may elucidate how users experience the product, service, or therapy  
22  
23 11 environment.<sup>17</sup>  
24  
25  
26  
27  
28  
29  
30

31 13 The primary aim of this review is to explore patient experiences of co-designed interventions  
32  
33 14 in rehabilitation hospitals. Secondary aims will be to understand (i) the methods used to co-  
34  
35 15 design rehabilitation interventions; (ii) the ways in which co-designed rehabilitation  
36  
37 16 interventions are implemented; and (iii) the barriers and facilitators to implementing co-  
38  
39 17 designed rehabilitation therapies. Our analysis will clarify patient experiences during both the  
40  
41 18 co-design and implementation phases of rehabilitation.  
42  
43  
44  
45  
46  
47

## 48 20 **METHODS AND ANALYSIS**

49  
50 21 Systematic reviews provide high-quality evidence syntheses to enable appraisal of policies  
51  
52 22 and clinical practice.<sup>18, 19</sup> A rapid review is an evidence synthesis that provides information  
53  
54 23 to decision makers in a timely manner, allowing for rapid communication of research  
55  
56 24 findings to end-users.<sup>20</sup> Components of a standard systematic review are streamlined in a  
57  
58 25 rapid review, to enable fast completion and dissemination.<sup>21</sup> Rapid reviews are particularly  
59  
60

Revision 28 Dec 2021

1  
2  
3 1 valuable when stakeholders have a short deadline for evidence and advice.<sup>19,20</sup> It is  
4  
5 2 noteworthy that rapid reviews are rigorous and are not less systematic than standard  
6  
7 3 systematic reviews.<sup>22</sup> The Cochrane Rapid Review Methods Group gives recommendations  
8  
9 4 on the methodology supporting rapid reviews.<sup>20,21</sup> These include a reduced number of  
10  
11 5 reviewers for screening, streamlining data extraction, and method quality appraisal processes,  
12  
13 6 and restricting the inclusion criteria to a defined date range.<sup>20</sup> They also recommend limiting  
14  
15 7 the number of databases searched and minimising grey literature and supplemental  
16  
17 8 searching.<sup>21</sup>

18  
19  
20  
21  
22  
23 10 The current protocol has been published on the international prospective register of  
24  
25 11 systematic reviews (PROSPERO: CRD42021264547) for registration, in compliance with the  
26  
27 12 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)  
28  
29 13 recommendations.<sup>23</sup> In the absence of a published reporting guideline for rapid reviews,<sup>18</sup> the  
30  
31 14 protocol will be informed by the PRISMA-P guidelines and the Cochrane Rapid Review  
32  
33 15 methods.<sup>21,23</sup> The review methods will also be guided by the Cochrane Rapid Review  
34  
35 16 Methods Group best practice recommendations and the Preferred Reporting Items for  
36  
37 17 Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>21,24</sup> The Enhancing  
38  
39 18 Transparency in Reporting the synthesis of Qualitative research (ENTREQ) guideline will  
40  
41 19 enable reporting of qualitative elements of the evidence synthesis.<sup>25</sup>

## 21 **Patient and public involvement**

22 This protocol has been co-designed and co-authored with two consumer representatives.  
23 Consumers offer an authentic lived-experience contribution, and the consumer  
24 representatives assisted in the conceptualisation of the protocol, the refinement of the  
25 research question, and the editing of the manuscript. The consumers will also provide input  
26 into the evidence synthesis and assist in writing the final manuscript for the rapid review.

Revision 28 Dec 2021

## 1 Eligibility criteria

2 Studies are to be included when they meet the following criteria: published papers in journals  
3 or conference proceedings; inclusion of participants who are adults older than 18 years;  
4 conducted in a physical rehabilitation setting, such as neuro-rehabilitation, musculoskeletal  
5 rehabilitation or cardiorespiratory rehabilitation, acute, sub-acute or slow stream  
6 rehabilitation; include rehabilitation interventions that are co-designed with patients; report  
7 patient experiences of co-designed rehabilitation interventions; inpatient hospital settings;  
8 empirical study design reported in English. Any study design will be included, such as  
9 randomised controlled clinical trials (RCT), non-randomised trials, cohort studies, pilot  
10 studies, feasibility analyses, single case designs, surveys, and qualitative investigations.

11  
12 Publications will be excluded if they pertain to drug, alcohol, vocational or psychiatric  
13 rehabilitation; relate to rehabilitation in the home or outpatient settings; are protocols, book  
14 chapters, theses, editorials, conference abstracts without an accompanying paper; are solely  
15 on paediatric or maternity participants; or if they are on patient groups that require a third  
16 party to participate in the co-design process (e.g., individuals with severe cognitive  
17 impairment, dementia or delirium or those in intensive care).

## 19 Identification and selection of included papers

20 A health services librarian will develop the search strategies and run the electronic database  
21 searches. Four online databases (Cochrane CENTRAL, MEDLINE, Embase, and CINAHL)  
22 will be searched for papers published from 1 January 2000 to 1 January 2022. Search terms  
23 for the following key concepts will be used: co-design; rehabilitation interventions;  
24 consumers and patients; patient experience; hospitals and acute health care settings. A draft  
25 example of the search strategy is given in Supplementary File 1.

Revision 28 Dec 2021

1  
2  
3 1 The search results will be downloaded to EndNote X9.3.1.<sup>26</sup> The combined yield will be  
4  
5 2 uploaded into Covidence® to sort and select the studies against the eligibility criteria.<sup>27</sup>  
6  
7 3 Initially the duplicates will be deleted in Covidence then titles alone will be screened for  
8  
9 4 eligibility. The remaining titles with abstracts will then be screened in Covidence. At least  
10  
11 5 one quarter of the titles with abstracts will be screened by two reviewers through applying the  
12  
13 6 eligibility criteria.<sup>20</sup> The remaining titles with abstracts will be screened by one reviewer.  
14  
15  
16 7 After reaching consensus on the yield, the full texts will be obtained for the remaining  
17  
18 8 abstracts. The full texts will be saved in Covidence, read in full by at least one reviewer and  
19  
20 9 screened using the eligibility criteria. A second reviewer will screen the excluded abstracts  
21  
22 10 and full text studies and the two reviewers will meet to reach consensus.<sup>20</sup> Reasons for  
23  
24 11 exclusions will be noted. Any discrepancies or disagreements that arise during this process  
25  
26 12 will be resolved by consultation and consensus with a third author. A PRISMA-compliant  
27  
28 13 flow chart (Supplementary File 2) will record the selection process for the included studies.  
29  
30  
31  
32  
33  
34

### 35 **Method quality assessment**

36  
37 16 Summary tables will document key elements for each investigation, such as the setting, co-  
38  
39 17 design strategy, co-designed interventions and evaluation. The Cochrane Risk of Bias tool  
40  
41 18 will be used to appraise the method quality for the RCTs.<sup>28</sup> For the non-randomised trials,  
42  
43 19 checklists from The Joanna Briggs Institute (JBI) critical appraisal tools will be completed to  
44  
45 20 assess method quality and the risk of bias, matched to different quantitative or qualitative  
46  
47 21 designs.<sup>29, 30</sup> This includes for survey and interview data, which will be summarised,  
48  
49 22 tabulated and analysed for themes.  
50  
51  
52  
53  
54  
55

56 24 Two reviewers will assess the included studies using the Cochrane Risk of Bias tool or  
57  
58 25 relevant JBI critical appraisal checklist to independently assess the trustworthiness of the  
59  
60

Revision 28 Dec 2021

1  
2  
3 1 included studies.<sup>28, 29</sup> The checklists include a series of questions which will help the  
4  
5 2 reviewers to determine the risk of bias and the trustworthiness of the results. Each checklist  
6  
7 3 has a comprehensive guide for each item.<sup>29, 31</sup>  
8  
9 4

### 5 **Data extraction and management**

6 Two reviewers will independently extract the data into spreadsheets using headings such as:  
7 study design, country, first author, year, setting, sample size, participant characteristics,  
8 intervention characteristics (content, who delivered, dosage etc.), co-design strategies used,  
9 description of co-design implementation, primary and secondary outcome measures such as  
10 patient experience and effects of co-production, outcome data and results, themes, co-design  
11 barriers, and co-design facilitators. The data extraction spreadsheets will be evaluated for  
12 consistency and any disagreements will be discussed and agreed upon. The spreadsheets will  
13 then be combined for the data synthesis stage.  
14

### 15 **Data analysis/synthesis**

16 Data analysis will be independently completed by two reviewers. The quantitative data will  
17 be reported according to the Synthesis without Meta-Analysis (SWiM).<sup>32</sup> Two reviewers will  
18 independently summarise and interpret the reported results for the included studies. A textual  
19 description will be provided for each study to give details on the setting, participants,  
20 intervention, and findings such as effect sizes or mean changes.<sup>29</sup>  
21

22 For the qualitative data, a thematic synthesis will be used within a theoretical framework of  
23 meta-synthesis and an analytical framework of thematic analysis.<sup>33</sup> The three stages of  
24 thematic synthesis recommended by Harden and Thomas (2008) will be used for combined  
25 analysis of the primary studies.<sup>34</sup> This includes coding the findings of the included studies  
26

Revision 28 Dec 2021

1  
2  
3 1 and developing descriptive themes for the combined coding; identifying relationships  
4  
5 2 between the descriptive themes; and generating analytical themes which transcend the  
6  
7 3 content of each original study.<sup>34</sup> This synthesis approach is supported by the Cochrane  
8  
9 4 Qualitative and Implementation Methods Group recommendations. They advise descriptive  
10  
11 5 themes often inform policy and analytical themes inform theory. Two reviewers will  
12  
13 6 independently read the included studies to code and extract the themes reported by the  
14  
15 7 authors of each paper. The reviewers will then group themes according to their similarities,  
16  
17 8 forming representative themes. From the consolidated themes, analytical themes will be  
18  
19 9 developed independently by each reviewer and finalised by consensus.<sup>34</sup> Summary tables will  
20  
21 10 be used for the qualitative findings. Discrepancies between the two reviewers will be resolved  
22  
23 11 by a third author.  
24  
25  
26  
27  
28  
29

### 30 **Confidence in cumulative evidence**

31  
32 14 PRIMSA-P recommends that the overall strength of included studies be assessed.<sup>23</sup> For  
33  
34 15 randomised controlled clinical trials and observational studies, the Grading of  
35  
36 16 Recommendations Assessment, Development and Evaluation (GRADE) framework will be  
37  
38 17 utilised.<sup>35</sup> This provides a quality of evidence rating system for each review outcome. The  
39  
40 18 results will be displayed in a table summarising the findings.<sup>35</sup>  
41  
42  
43  
44  
45

46 20 Where the included studies are of a qualitative design, the strength of the findings will be  
47  
48 21 measured using the GRADE-CERQual (Confidence in Evidence from Reviews of Qualitative  
49  
50 22 Research).<sup>36</sup> The GRADE-CERQual is a framework for reviewers to assess the amount of  
51  
52 23 confidence they can have in the review results from qualitative syntheses.<sup>36</sup> Two reviewers  
53  
54 24 (JPM, SCS) will independently perform a GRADE-CERQual assessment of the findings of  
55  
56 25 each review.  
57  
58  
59  
60

Revision 28 Dec 2021

1  
2  
3 1 **RESULTS**

4  
5 2 The quantitative results will be presented as statistical analyses, summary tables, flow charts,  
6  
7 3 and narrative summaries. The qualitative results will be presented as themes and subthemes  
8  
9 4 and summary tables linked to the data.  
10  
11

12 5  
13  
14 6 **DISCUSSION**

15  
16 7 The rationale and design of a rapid review of patient experiences of co-design of  
17  
18 8 rehabilitations interventions has been described. The review will identify important factors in  
19  
20 9 co-production and inform optimum intervention design for movement rehabilitation.  
21  
22

23 10  
24  
25 11 **ETHICS AND DISSEMINATION**

26  
27  
28 12 Ethics approval will not be required for the protocol and rapid review. The protocol and  
29  
30 13 accompanying review will be submitted to an international peer-reviewed journal for  
31  
32 14 publication. The evidence will be rapidly translated to the research community, policy  
33  
34 15 makers, consumers, health professionals and healthcare organisations using a range of  
35  
36 16 implementation science methods.<sup>37, 38</sup> We shall hold a series of consumer workshops online  
37  
38 17 and face-to-face, to share the results with end users. A series of digital health seminars will be  
39  
40 18 conducted on the results using the Academic and Research Collaborative in Health (ARCH)  
41  
42 19 online platform. The findings will also be presented at workshops and conferences and  
43  
44 20 disseminated to health professionals at in professional development seminars. An evidence  
45  
46 21 summary will be posted online via social media, and on websites, to ensure that the findings  
47  
48 22 have wide reach.  
49  
50  
51  
52

53 23

54  
55 24

56  
57 25

58  
59  
60



Revision 28 Dec 2021

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Acknowledgements**

We thank Elizabeth Lawrence, La Trobe University librarian, for developing and conducting the search of the literature.

## **Author Contribution**

JPM, SCS, JJ, and MEM contributed to the concept and design of the study, research question and acquisition of data and resources. JPM, SCS, JJ, AH, MK, JG, JW and MEM contributed to the planning, conduct and reporting of the work in this paper. JPM wrote the first draft of the protocol manuscript. All authors contributed to the subsequent drafts of the manuscript. The final draft was edited and approved by all authors prior to submission (JPM, SCS, JJ, AH, MK, JG, JW and MEM).

**Funding:** This project was funded by the La Trobe University, Academic and Research Collaborative in Health (ARCH).

**Competing interests:** None declared

**Data statement:** Data sharing is not applicable as no participant datasets will be generated and/or analysed for this study.

Revision 28 Dec 2021

1  
2  
3 **1 REFERENCE LIST**  
4

- 5  
6 2 1. Bombard Y, Baker GR, Orlando E, et al. Engaging patients to improve quality of  
7  
8 3 care: a systematic review. *Implementation Science*. 2018;13(1):98.  
9  
10 4 2. Merner B, Hill S, Colombo C, et al. Consumers and health providers working in  
11  
12 5 partnership for the promotion of person-centred health services: a co-produced qualitative  
13  
14 6 evidence synthesis. *Cochrane Database of Systematic Reviews*. 2019(2).  
15  
16 7 3. Wolfe JA, Niederhauser V, Marshburn D, et al. Defining Patient Experience. *Patient*  
17  
18 8 *Experience Journal*. 2014;1(1).  
19  
20 9 4. ACSQHC. Partnering with consumers standard. 2019 Available from:  
21  
22 10 47  
48 22 Codesign-Capability.pdf.  
49  
50  
51 23 10. Lim S, Morris H, Pizzirani B, et al. Evaluating hospital tools and services that were  
52  
53  
54 24 co-produced with patients: A rapid review. *Int J Qual Health Care*. 2020;32(4):231-9.  
55  
56  
57  
58  
59  
60

Revision 28 Dec 2021

- 1 11. Wolstenholme D, Grindell C, Dearden A. A co-design approach to service  
2 improvement resulted in teams exhibiting characteristics that support innovation. Design for  
3 health (Abingdon, England). 2017;1(1):42-58.
- 4 12. Pelton L, Knihtila M. Experience-Based Co-Design of Health Care Services  
5 Implementation Guide. Boston, Massachusetts: Institute for Healthcare Improvement; 2018  
6 Available from: <http://www.ihl.org/>.
- 7 13. Slattery P, Saeri AK, Bragge P. Research co-design in health: a rapid overview of  
8 reviews. Health Research Policy and Systems. 2020;18(1):17.
- 9 14. Clarke D, Jones F, Harris R, et al. What outcomes are associated with developing and  
10 implementing co-produced interventions in acute healthcare settings? A rapid evidence  
11 synthesis. BMJ Open. 2017;7(7):e014650.
- 12 15. Noorbergen TJ, Adam MTP, Roxburgh M, et al. Co-design in mHealth Systems  
13 Development: Insights from a systematic literature review. Association for Information  
14 Systems transactions on human-computer interaction. 2021;13(2):175-205.
- 15 16. Aljaroodi HM, Adam M, Chiong R, et al. Empathic Avatars in Stroke Rehabilitation:  
16 A Co-designed mHealth Artifact for Stroke Survivors 2017. 73-89 p.
- 17 17. Sanders EBN, Stappers PJ. Probes, toolkits and prototypes: three approaches to  
18 making in codesigning. CoDesign. 2014;10(1):5-14.
- 19 18. Stevens A, Garritty C, Hersi M, et al. Developing PRISMA-RR, a reporting guideline  
20 for rapid reviews of primary studies (Protocol). 2018.
- 21 19. Higgins J, Green S, Cochrane C, et al. Cochrane handbook for systematic reviews of  
22 interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell; 2008.
- 23 20. Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane Rapid Reviews  
24 Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin  
25 Epidemiol. 2021;130:13-22.

Revision 28 Dec 2021

- 1  
2  
3 1 21. Garritty C, Gartlehner G, Kamel C, et al. Cochrane Rapid Reviews. Interim Guidance  
4  
5 2 from the Cochrane Rapid Reviews Methods Group March 2020. Available from:  
6  
7 3 [https://methods.cochrane.org/rapidreviews/sites/methods.cochrane.org.rapidreviews/files/pub](https://methods.cochrane.org/rapidreviews/sites/methods.cochrane.org.rapidreviews/files/public/uploads/cochrane_rr_-_guidance-23mar2020-final.pdf)  
8  
9 4 [lic/uploads/cochrane\\_rr\\_-\\_guidance-23mar2020-final.pdf](https://methods.cochrane.org/rapidreviews/sites/methods.cochrane.org.rapidreviews/files/public/uploads/cochrane_rr_-_guidance-23mar2020-final.pdf).  
10  
11 5 22. Moons P, Goossens E, Thompson DR. Rapid reviews: the pros and cons of an  
12  
13 6 accelerated review process. *European Journal of Cardiovascular Nursing*. 2021;20(5):515-9.  
14  
15 7 23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic  
16  
17 8 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*.  
18  
19 9 2015;4(1):1.  
20  
21 10 24. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated  
22  
23 11 guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.  
24  
25 12 25. Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the  
26  
27 13 synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol*. 2012;12(1):181-  
28  
29 14 26. Endnote reference management software, Clarivate Analytics [Available from:  
30  
31 15 [www.endnote.com](http://www.endnote.com).  
32  
33 16 27. Covidence systematic review software. Available from: [www.covidence.org](http://www.covidence.org).  
34  
35 17 28. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of  
36  
37 18 bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919.  
38  
39 19 29. Aromataris E, Munn Z (Editors). *JBIM Manual for Evidence Synthesis 2020*. Available  
40  
41 20 from: <https://synthesismanual.jbi.global>. <https://doi.org/10.46658/JBIMES-20-01>.  
42  
43 21 30. Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological  
44  
45 22 guidance for systematic reviewers utilizing meta-aggregation. *Int J Evid Based Healthc*.  
46  
47 23 2015;13(3):179-87.  
48  
49 24 31. Higgins J, Savović J, Page M, et al. Chapter 8: Assessing risk of bias in a randomized  
50  
51 25 trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA  
52  
53  
54  
55  
56  
57  
58  
59  
60

Revision 28 Dec 2021

- 1  
2  
3 1 (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated  
4  
5 2 February 2021). Cochrane, 2021. Available from: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).  
6  
7 3 32. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis  
8  
9 4 (SWiM) in systematic reviews: reporting guideline. *BMJ*. 2020;368:l6890.  
10  
11 5 33. Noyes J, Booth A, Cargo M, et al. Chapter 21: Qualitative evidence. In: Higgins JPT,  
12  
13 6 Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane  
14  
15 7 Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021).  
16  
17 8 Cochrane, 2021.  
18  
19 9 34. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in  
20  
21 10 systematic reviews. *BMC Med Res Methodol*. 2008;8(1):45-.  
22  
23 11 35. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines. *J Clin Epidemiol*.  
24  
25 12 2011;64(4):383-94.  
26  
27 13 36. Lewin S, Booth A, Glenton C, et al. Applying GRADE-CERQual to qualitative  
28  
29 14 evidence synthesis findings: introduction to the series. *Implementation Science*. 2018;13(1):2.  
30  
31 15 37. Greenhalgh T, Papoutsi C. Spreading and scaling up innovation and improvement.  
32  
33 16 *BMJ*. 2019;365:l2068.  
34  
35 17 38. Sarkies MN, Robins LM, Jepson M, et al. Effectiveness of knowledge brokering and  
36  
37 18 recommendation dissemination for influencing healthcare resource allocation decisions: A  
38  
39 19 cluster randomised controlled implementation trial. *PLOS Medicine*. 2021;18(10):e1003833.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Draft of Medline Search Strategy

(with example interim results)

Database(s): Ovid MEDLINE(R) ALL

Search ID#	Search Terms	Search Notes	Results
1	(co-design* or codesign*).mp.		1614
2	(co-produc* or coproduc*).mp.		5418
3	(codevise* or cocreate* or co-create* or co-invent* or cogenerate* or co-found*).mp.		914
4	participatory design*.mp.		623
5	collaborative design*.mp.		138
6	("Experience based" adj2 design*).mp.		99
7	Decision Making, Shared/		1005
8	(share* adj2 "decision making").mp.		10869
9	or/1-8		19259
10	patient engagement.mp.		3550
11	patient involvement.mp.		2896
12	patient consultation.mp.		560
13	Patient Participation/		27250
14	patient participation.mp.		29017
15	patient input*.mp.		419
16	Stakeholder Participation/		1578
17	stakeholder participation.mp.		1906
18	consumer engagement.mp.		253
19	consumer involvement.mp.		357
20	consumer participation.mp.		414
21	consumer input.mp.		99
22	or/10-21		36540
23	design*.mp.		2282168
24	22 and 23	more general co-design terms AND "design"	7842
25	9 or 24	Co-design terms	26095
26	exp Hospitals/		287515
27	hospital*.tw.		1381782

28	Critical Care/		55257
29	Inpatients/		24172
30	inpatient*.mp.		128467
31	Hospitalization/		117596
32	hospitali?ation.mp.		234243
33	exp Hospital Units/		119558
34	ward*.tw,kw.		64380
35	((acute or subacute or sub-acute) adj3 (clinic* or care or department* or unit* or centre* or center*)).mp.		60190
36	Subacute Care/		1211
37	or/26-36	Hospital terms	1722776
38	(patient* adj2 (experience* or perception* or belief* or believe* or participat*)).mp.		170925
39	(consumer* adj2 (experience* or perception* or belief* or believe* or participat*)).mp.		2655
40	lived experience*.mp.		7501
41	38 or 39 or 40	Outcomes terms	180025
42	25 and 37 and 41		1790
43	limit 42 to (english language and yr="2000 -Current")		1592

NOTE: [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

# Draft of Embase Search Strategy

(with example interim results)

Database(s): **Embase Classic+Embase**

Search ID#	Search Terms	Search Notes	Results
1	(co-design* or codesign*).mp.		2011
2	(co-produc* or coproduc*).mp.		6311
3	(codevise* or cocreate* or co-create* or co-invent* or cogenerate* or co-found*).mp.		1316
4	participatory design*.mp.		658
5	collaborative design*.mp.		185
6	("Experience based" adj2 design*).mp.		156
7	shared decision making/		9161
8	(share* adj2 "decision making").mp.		17648
9	or/1-8		27744
10	patient engagement.mp.		5154
11	patient involvement.mp.		4006
12	patient consultation.mp.		905
13	patient participation/		29537
14	patient participation.mp.		31308
15	patient input*.mp.		882
16	stakeholder engagement/		3763
17	stakeholder participation.mp.		424
18	consumer engagement.mp.		377
19	consumer involvement.mp.		521
20	consumer participation.mp.		674
21	consumer input.mp.		158
22	or/10-21		43839
23	design*.mp.		2618705
24	22 and 23		8921
25	9 or 24		35753
26	exp hospital/		1309237
27	hospital*.tw.		2200888
28	intensive care/		131889
29	hospital patient/		194627



30	inpatient*.mp.		201483
31	hospitalization/		424891
32	hospitali?ation.mp.		527240
33	exp "hospital subdivisions and components"/		631311
34	ward*.tw,kw.		104585
35	((acute or subacute or sub-acute) adj3 (clinic* or care or department* or unit* or centre* or center*)).mp.		90253
36	subacute care/		1177
37	or/26-36		3091932
38	(patient* adj2 (experience* or perception* or belief* or believe* or participat*)).mp.		265842
39	(consumer* adj2 (experience* or perception* or belief* or believe* or participat*)).mp.		3293
40	lived experience*.mp.		9078
41	38 or 39 or 40		276832
42	25 and 37 and 41		2366
43	limit 42 to (english language and yr="2000 -Current")		2255

NOTE: [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]

# Draft of CINAHL Search Strategy

(with example interim results)

Search ID#	Search Terms	Search Notes	Results
S1	co-design* or codesign*		948
S2	co-product* or coproduc*		1,084
S3	codevise* or cocreate* or co-create* or co-invent* or cogenerate* or co-found*		1,026
S4	"participatory design**"		330
S5	"collaborative design**"		81
S6	"Experience based" N2 design*		79
S7	(MH "Decision Making, Shared")		2,159
S8	share* N2 "decision making"		7,201
S9	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8		10,509
S10	"patient engagement"		2,133
S11	"patient involvement"		1,602
S12	"patient consultation"		217
S13	"patient participation"		1,532
S14	"patient input**"		199
S15	(MH "Stakeholder Participation")		1,435
S16	"stakeholder participation"		1,527
S17	"consumer engagement"		208
S18	"consumer involvement"		228
S19	(MH "Consumer Participation")		21,333
S20	"consumer participation"		21,416
S21	"consumer input"		72
S22	S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21		26,691
S23	design*		871,880
S24	S22 AND S23		5,274
S25	S9 OR S24		15,237
S26	(MH "Hospitals+")		122,030

S27	TI hospital* OR AB hospital*		484,543
S28	(MH "Critical Care")		24,037
S29	(MH "Inpatients")		84,408
S30	inpatient*		123,011
S31	(MH "Hospitalization")		39,453
S32	hospitalization or hospitalisation		83,875
S33	(MH "Hospital Units+")		101,055
S34	TI ward* OR AB ward*		29,373
S35	(acute or subacute or sub-acute) N3 (clinic* or care or department* or unit* or centre* or center*)		41,004
S36	(MH "Subacute Care")		1,780
S37	S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36		710,289
S38	patient* N2 (experience* or perception* or belief* or believe* or participat*)		72,462
S39	consumer* N2 (experience* or perception* or belief* or believe* or participat*)		22,773
S40	"lived experience"		5,252
S41	S38 OR S39 OR S40		97,797
S42	S25 AND S37 AND S41		1,177
S43	S25 AND S37 AND S41	Limiters - English Language; Published Date: 20000101-20211231	1,107


# Draft of Cochrane Search Strategy

(with example interim results)

Search ID#	Search Terms	Search Notes	Results
#1	co-design* OR codesign*		194
#2	co-produc* or coproduc*		120
#3	codevise* or cocreate* or co-create* or co-invent* or cogenerate* or co-found*		119
#4	participatory NEXT design*		47
#5	collaborative NEXT design*		12
#6	Experience based NEAR/2 design		12
#7	MeSH descriptor: [Decision Making, Shared] this term only		36
#8	share* NEAR/2 "decision making"		1657
#9	{OR #1-#8}		2125
#10	patient engagement		587
#11	patient involvement		462
#12	patient consultation		142
#13	MeSH descriptor: [Patient Participation] this term only		1427
#14	patient participation		2979
#15	patient NEXT input*		56
#16	MeSH descriptor: [Stakeholder Participation] this term only		19
#17	stakeholder participation		31
#18	consumer engagement		26
#19	consumer involvement		75
#20	consumer participation		150
#21	consumer input		31
#22	{OR #10-#21}		4107
#23	design*		295537
#24	#22 AND #23		1718
#25	#9 OR #24		3634
#26	MeSH descriptor: [Hospitals] explode all trees		3713
#27	hospital*:ti,ab		170151
#28	MeSH descriptor: [Critical Care] this term only		1773
#29	MeSH descriptor: [Inpatients] this term only		987

#30	inpatient*		21072
#31	MeSH descriptor: [Hospitalization] this term only		5397
#32	hospitalization OR hospitalisation		44727
#33	MeSH descriptor: [Hospital Units] explode all trees		4254
#34	ward*:ti,ab,kw		13937
#35	(acute or subacute or sub-acute) NEAR/3 (clinic* or care or department* or unit* or centre* or center*)		8705
#36	MeSH descriptor: [Subacute Care] this term only		19
#37	{OR #26-#36}		199880
#38	patient* NEAR/2 (experience* or perception* or belief* or believe* or participat*)		32637
#39	consumer* NEAR/2 (experience* or perception* or belief* or believe* or participat*)		316
#40	lived NEXT experience*		237
#41	{OR #38-#40}		33076
#42	#25 AND #37 AND #41		499
		Central (Trials only)	378

## Appendix 2: PRISMA flow Diagram:



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

## PRISMA-P 2015 checklist: recommended items to address in a systematic review protocol

Section & topic	Item no:	Checklist item	Page & Line
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	Page 1, line 2
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	Page 3, line 4
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	Page 1, lines 8-11
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	Page 1, lines 4-5,
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support			
Sources	5a	Indicate sources of financial or other support for the review	Page 12, lines 18-19
Sponsor	5b	Provide name for the review funder and/or sponsor	Page 12, lines 18-19
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	Page 12, lines 18-19
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	Page 5, lines 2-13
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	Page 5, lines 15-20
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	Page 7, lines 4-19
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	Page 7 lines 23-24
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Supplemental file 1
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	Page 8, lines 5-

			6. Page 9, line 11.
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	Page 8, lines 5-18
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	Page 9, lines 11-18
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	Page 7, lines 4-19
Outcomes & prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	Page 7, lines 8-9
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	Page 8, lines 22-25. Page 9, lines 1-8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	Page 9, lines 21-24
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	Page 9, lines 21-24
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Page 9, lines 21-24
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	Page 10, lines 4-18
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Page 10, lines 21-25. Page 11, lines 2-7
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	Page 10, lines 21-25. Page 11, lines 2-7